ReviewPathogens (Basel, Switzerland)2025
Innovations in Biofilm Prevention and Eradication in Medical Sector: An Integrative Review.
Review in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiofilm-associated infections remain a major challenge in modern medicine due to their high resistance to antibiotics and immune defences. Advances in materials science, chemistry, and nanotechnology have led to the development of innovative, non-antibiotic approaches to prevent or eradicate biofilms.
methodsThis review summarises antibiofilm strategies reported between 2020 and 2025, grouped into chemical, enzymatic, physical-photonic, nanomaterial-based, and biological hybrid categories.
resultsChemical methods such as silver-based chemical systems, nitric oxide donors, and biosurfactants disrupt bacterial membranes, generate reactive oxygen species, and inhibit quorum sensing. Enzymatic coatings with DNase I or lysostaphin effectively reduce
conclusionsRecent antibiofilm innovations mark a transition from conventional antibiotics to multifunctional and adaptive systems integrating chemical, enzymatic, and physical mechanisms for effective biofilm control on medical surfaces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.